Promising Results from the EMPRESS Study Highlight Giredestrant's Efficacy in Treating Early-Stage ER+/HER2- Breast Cancer The EMPRESS study showcases giredestrant's potential in treating early-stage ER+/HER2- breast cancer without ovarian suppression, promising better outcomes for patients.

Promising Results from the EMPRESS Study Highlight Giredestrant's Efficacy in Treating Early-Stage ER+/HER2- Breast Cancer #None #Breast_Cancer #EMPRESS_study #giredestrant